Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic
fatty liver disease (NAFLD) is increasing both in Europe and the United States, becoming …

Nonalcoholic steatohepatitis (NASH) has become a focus for drug development owing to its
increasing prevalence and health care burden. The global prevalence of NASH is estimated …

Background Outcomes after liver resection (LR) and liver transplantation (LT) for
hepatocellular carcinoma (HCC) are heterogenous and may vary by region, over time …

Nonalcoholic steatohepatitis (NASH) cirrhosis is the fastest growing indication for liver
transplantation (LT) in the United States. We aimed to determine the temporal trend behind …

Objective: Normothermic machine perfusion (NMP) enables optimized ex-vivo preservation
of a donor liver in a normal physiologic state. The impact of this emerging technology on …

Background Published reports describing the national experience with liver grafts from
donation after cardiac death (DCD) donors have resulted in reservations with their …

The use of liver grafts from donation after cardiac death (DCD) has been limited due to the
increased rate of graft failure, mostly related to ischemic cholangiopathy (IC). It is our …

Background Liver transplantation is the only curative treatment option for end-stage liver
disease; however, its use remains limited due to a shortage of suitable organs. In recent …

The role of donation after cardiac death (DCD) in expanding the donor pool is mainly limited
by the incidence of primary nonfunction (PNF) and ischemia‐related complications. Even …

Hepatocellular carcinoma (HCC) is a major cause of cancer death and is increasing in
incidence. This review focuses on HCC surveillance and treatment of early-stage disease …